Stem Cell Clinic

Wave Life Sciences to Host Analyst and Investor Virtual Event, “Towards the Clinic: Spotlight on RNA Editing for AATD,” on September 28, 2022

Focus on WVE-006, a first-in-class RNA editing development candidate for AATD, and feature AATD expert presentation Focus on WVE-006, a first-in-class RNA editing development candidate for AATD, and feature AATD expert presentation

See the original post:
Wave Life Sciences to Host Analyst and Investor Virtual Event, “Towards the Clinic: Spotlight on RNA Editing for AATD,” on September 28, 2022

Benitec Biopharma Inc. Announces Closing of $18 Million Underwritten Public Offering

HAYWARD, Calif., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced it closed its previously announced underwritten public offering of 29,809,471 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying warrants to purchase up to 29,809,471 shares of common stock. Each share of common stock (or pre-funded warrant in lieu thereof) was sold together with one common warrant to purchase one share of common stock at a combined offering price of $0.60. The warrants will be exercisable commencing on the effective date of an increase in our authorized shares of common stock at an exercise price of $0.66 per share of common stock and will expire on the fifth anniversary of such initial exercise date.

Here is the original post:
Benitec Biopharma Inc. Announces Closing of $18 Million Underwritten Public Offering

Myovant Recognizes Prostate Cancer Awareness Month with Educational Sponsorships and Online Campaign to Encourage Patients to Speak Up, Seek Support…

Peer Video Series Campaign and Educational Sponsorships Spotlight Patient Barriers to Conversations Peer Video Series Campaign and Educational Sponsorships Spotlight Patient Barriers to Conversations

Read more from the original source:
Myovant Recognizes Prostate Cancer Awareness Month with Educational Sponsorships and Online Campaign to Encourage Patients to Speak Up, Seek Support...

Revolo Biotherapeutics to Participate in the Sachs Associates 22nd Annual Biotech in Europe Forum for Global Partnering and Investment

NEW ORLEANS and LONDON, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced that it will be participating in the Sachs Associates 22nd Annual Biotech in Europe Forum for Global Partnering and Investment taking place in Basel, Switzerland from September 21-22.

Follow this link:
Revolo Biotherapeutics to Participate in the Sachs Associates 22nd Annual Biotech in Europe Forum for Global Partnering and Investment

ORION CORPORATION: ACQUISITION OF OWN SHARES 16.09.2022

See more here:
ORION CORPORATION: ACQUISITION OF OWN SHARES 16.09.2022

Larimar Therapeutics Announces Closing of Underwritten Offering and Full Exercise of Option to Purchase Additional Shares

BALA CYNWYD, Pa., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar” or the “Company”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the closing of its previously announced underwritten offering of 25,558,750 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase an additional 3,333,750 shares at the offering price of $3.15 per share. The gross proceeds to Larimar, before deducting the underwriting discounts and commissions and estimated offering expenses, were approximately $80.5 million.

Read the rest here:
Larimar Therapeutics Announces Closing of Underwritten Offering and Full Exercise of Option to Purchase Additional Shares

AltruBio President and CEO Judy Chou to Participate at the Longwood Healthcare Leaders Fall Webconference

SAN FRANCISCO, Sept. 16, 2022 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment of immunological diseases with high unmet medical needs, today announced that AltruBio President and CEO Dr. Judy Chou will speak on “The Next Wave of Targeted Therapies” at the Longwood Healthcare Leaders Fall Webconference on Wednesday, September 21, 2022.

Read more:
AltruBio President and CEO Judy Chou to Participate at the Longwood Healthcare Leaders Fall Webconference

Beyond Air® To Participate in Three Upcoming Investor Conferences

GARDEN CITY, N.Y., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced that the Company is scheduled to participate in a fireside chat at the LifeSci Partners HealthTech Symposium being held virtually September 20-21, 2022. Additionally, Steve Lisi, Chairman and CEO of Beyond Air, will be presenting corporate overviews and participating in 1x1 meetings at the Ladenburg Thalmann Healthcare Conference being held Thursday, September 29, 2022 at the Sofitel Hotel New York and the Roth Inaugural Healthcare Opportunities Conference on October 6, 2022 in New York City.

More here:
Beyond Air® To Participate in Three Upcoming Investor Conferences

POINT Biopharma Announces Closing of Public Offering of 13,900,000 Shares of Common Stock

INDIANAPOLIS, Sept. 16, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to life-changing radiopharmaceuticals, today announced the closing of its previously announced underwritten public offering of 13,900,000 shares of Common Stock at a public offering price of $9.00 per share. The gross proceeds to the Company from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, were approximately $125 million.

See the original post here:
POINT Biopharma Announces Closing of Public Offering of 13,900,000 Shares of Common Stock

Clearmind Medicine Announces Share-Based Payment for one of the Company’s Consultants

VANCOUVER, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND), (OTC Pink: CMNDF), (FSE: CWY0) (“Clearmind” or the "Company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, announced that it has decided to issue 122,160 common shares in the capital of the Company ("Shares") in lieu of payment of $10,000, monthly, starting May 1st 2022, to consultants of the Company.

Originally posted here:
Clearmind Medicine Announces Share-Based Payment for one of the Company's Consultants